Erratum to: Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: A prospective cohort study (Thrombosis and Haemostasis (2018) 118 (2188) DOI: 10.1055/s-0038-1636541);Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Thrombosis and Haemostasis

Volumn 118, Issue 5, 2018, Pages 842-851

  Schulman, Sam ^a,b,j   Gross, Peter L ^a   Ritchie, Bruce ^c   Nahirniak, Susan ^c   Lin, Yulia ^d   Lieberman, Lani ^e   Carrier, Marc ^f   Crowther, Mark A ^a   Ghosh, Indy ^g   Lazo Langner, Alejandro ^h   Zondag, Michelle ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h Trillium Hospital   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j HHS General Hospital   (Canada)

more..

Author keywords

antagonists and inhibitors; apixaban; atrial fibrillation; haemorrhage; rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DALTEPARIN; HEMOSTATIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; WARFARIN;

AGED; ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELLULITIS; COHORT ANALYSIS; CREATININE CLEARANCE; DEATH; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATURIA; HUMAN; HYPERNATREMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL BLEEDING; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RETROPERITONEAL HEMORRHAGE; SPINAL CORD HEMORRHAGE; THROMBOEMBOLISM; THROMBOPHLEBITIS; VENOUS THROMBOEMBOLISM;

EID: 85044317277     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1675417     Document Type: Erratum

References (26)

1. Connolly S. J. Eikelboom J. Joyner C., et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med: 2011; 364 09 806 817
2. Giugliano R. P. Ruff C. T. Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
3. Patel M. R. Mahaffey K. W. Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
4. Piccini J. P. Garg J. Patel M. R., et al. ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J: 2014; 35 28 1873 1880
5. Chai-Adisaksopha C. Crowther M. Isayama T. Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood: 2014; 124 15 2450 2458
6. Hylek E. M. Held C. Alexander J. H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol: 2014; 63 20 2141 2147
7. Eerenberg E. S. Middeldorp S. Levi M. Lensing A. W. Büller H. R. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost: 2015; 13 09 1590 1596
8. Connolly S. J. Milling T. J. Jr. Eikelboom J. W., et al. ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med: 2016; 375 12 1131 1141
9. Goldstein J. N. Refaai M. A. Milling T. J. Jr., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet: 2015; 385 (9982): 2077 2087
10. Cheung Y. W. Barco S. Hutten B. A. Meijers J. C. Middeldorp S. Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost: 2015; 13 10 1799 1805
11. Eerenberg E. S. Kamphuisen P. W. Sijpkens M. K. Meijers J. C. Buller H. R. Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
12. Zahir H. Brown K. S. Vandell A. G., et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation: 2015; 131 01 82 90
13. Grandhi R. Newman W. C. Zhang X., et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg: 2015; 84 06 1956 1961
14. Majeed A. Ågren A. Holmström M., et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood: 2017; 130 15 1706 1712
15. Schulman S. Kearon C.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost: 2005; 3 04 692 694
16. Sarode R. Milling T. J. Jr. Refaai M. A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation: 2013; 128 11 1234 1243
17. Broderick J. P. Brott T. G. Duldner J. E. Tomsick T. Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke: 1993; 24 07 987 993
18. Khorsand N. Majeed A. Sarode R. Beyer-Westendorf J. Schulman S. Meijer K.; Subcommittee on Control of Anticoagulation. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J Thromb Haemost: 2016; 14 01 211 214
19. Marlu R. Hodaj E. Paris A. Albaladejo P. Cracowski J. L. Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost: 2012; 108 02 217 224
20. Kubitza D. Becka M. Zuehlsdorf M. Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol: 2007; 47 02 218 226
21. Mueck W. Lensing A. W. Agnelli G. Decousus H. Prandoni P. Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet: 2011; 50 10 675 686
22. Upreti V. V. Wang J. Barrett Y. C., et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol: 2013; 76 06 908 916
23. Yin O. Q. Tetsuya K. Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol: 2014; 70 11 1339 1351
24. Barco S. Whitney Cheung Y. Coppens M. Hutten B. A. Meijers J. C. Middeldorp S. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol: 2016; 172 02 255 261
25. Liotta E. M. Garg R. K. Temes R. E., et al. Warfarin-associated intracerebral hemorrhage is inadequately treated at community emergency departments. Stroke: 2012; 43 09 2503 2505
26. Pollack C. V. Jr. Reilly P. A. Eikelboom J., et al. Idarucizumab for dabigatran reversal. N Engl J Med: 2015; 373 06 511 520